These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 1690309)
1. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. Partin AW; Carter HB; Chan DW; Epstein JI; Oesterling JE; Rock RC; Weber JP; Walsh PC J Urol; 1990 Apr; 143(4):747-52. PubMed ID: 1690309 [TBL] [Abstract][Full Text] [Related]
2. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. Oesterling JE; Brendler CB; Epstein JI; Kimball AW; Walsh PC J Urol; 1987 Jul; 138(1):92-8. PubMed ID: 3599229 [TBL] [Abstract][Full Text] [Related]
3. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL. Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361 [TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. Stamey TA; Kabalin JN; McNeal JE; Johnstone IM; Freiha F; Redwine EA; Yang N J Urol; 1989 May; 141(5):1076-83. PubMed ID: 2468795 [TBL] [Abstract][Full Text] [Related]
5. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689 [TBL] [Abstract][Full Text] [Related]
6. The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. Carter HB; Partin AW; Epstein JI; Chan DW; Walsh PC J Urol; 1990 Nov; 144(5):1167-70; discussion 1170-1. PubMed ID: 1700143 [TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. Oesterling JE; Chan DW; Epstein JI; Kimball AW; Bruzek DJ; Rock RC; Brendler CB; Walsh PC J Urol; 1988 Apr; 139(4):766-72. PubMed ID: 2451037 [TBL] [Abstract][Full Text] [Related]
8. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. Partin AW; Yoo J; Carter HB; Pearson JD; Chan DW; Epstein JI; Walsh PC J Urol; 1993 Jul; 150(1):110-4. PubMed ID: 7685418 [TBL] [Abstract][Full Text] [Related]
9. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. Noguchi M; Stamey TA; McNeal JE; Yemoto CM J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712 [TBL] [Abstract][Full Text] [Related]
10. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252 [TBL] [Abstract][Full Text] [Related]
11. Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: an Indian experience. Singh P; Dogra PN; Gupta NP; Nayyar R; Seth A; Javali TD; Kumar R Indian J Cancer; 2011; 48(4):483-7. PubMed ID: 22293265 [TBL] [Abstract][Full Text] [Related]
12. Preoperative prostate-specific antigen in predicting pathologic stage and grade after radical prostatectomy. Winter HI; Bretton PR; Herr HW Urology; 1991 Sep; 38(3):202-5. PubMed ID: 1716021 [TBL] [Abstract][Full Text] [Related]
13. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate. Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940 [TBL] [Abstract][Full Text] [Related]
14. Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. Alexander RB; Maguire MG; Epstein JI; Walsh PC J Urol; 1989 Apr; 141(4):880-2. PubMed ID: 2926881 [TBL] [Abstract][Full Text] [Related]
15. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma]. Stamey TA Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883 [TBL] [Abstract][Full Text] [Related]
16. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Stock RG; Stone NN; Ianuzzi C; Unger P Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):815-21. PubMed ID: 7591888 [TBL] [Abstract][Full Text] [Related]
17. Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks. Tewari A; Narayan P J Urol; 1998 Aug; 160(2):430-6. PubMed ID: 9679892 [TBL] [Abstract][Full Text] [Related]
18. Value of prostate-specific antigen measurements in predicting lymph node involvement in prostatic cancer. Arai Y; Yoshiki T; Yamabe H; Yoshida O Urol Int; 1990; 45(6):356-60. PubMed ID: 1705062 [TBL] [Abstract][Full Text] [Related]
19. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715 [TBL] [Abstract][Full Text] [Related]